Filtros : "GRU999FBC" "Estados Unidos" Limpar

Filtros



Refine with date range


  • Source: Regulatory Toxicology and Pharmacology. Unidade: FCF

    Subjects: MUTAGÊNESE, TOXICOLOGIA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      WAECHTER, Fernanda et al. Retrospective application of ICH M7 to anti-hypertensive drugs in Brazil: risk assessment of potentially mutagenic impurities. Regulatory Toxicology and Pharmacology, v. 151, p. 1-12 art. 105669, 2024Tradução . . Disponível em: https://dx.doi.org/10.1016/j.yrtph.2024.105669. Acesso em: 04 nov. 2024.
    • APA

      Waechter, F., Oliveira, A. A. F., Shimada, A. L. B., Bernes Junior, E., & Nascimento, E. de S. (2024). Retrospective application of ICH M7 to anti-hypertensive drugs in Brazil: risk assessment of potentially mutagenic impurities. Regulatory Toxicology and Pharmacology, 151, 1-12 art. 105669. doi:10.1016/j.yrtph.2024.105669
    • NLM

      Waechter F, Oliveira AAF, Shimada ALB, Bernes Junior E, Nascimento E de S. Retrospective application of ICH M7 to anti-hypertensive drugs in Brazil: risk assessment of potentially mutagenic impurities [Internet]. Regulatory Toxicology and Pharmacology. 2024 ; 151 1-12 art. 105669.[citado 2024 nov. 04 ] Available from: https://dx.doi.org/10.1016/j.yrtph.2024.105669
    • Vancouver

      Waechter F, Oliveira AAF, Shimada ALB, Bernes Junior E, Nascimento E de S. Retrospective application of ICH M7 to anti-hypertensive drugs in Brazil: risk assessment of potentially mutagenic impurities [Internet]. Regulatory Toxicology and Pharmacology. 2024 ; 151 1-12 art. 105669.[citado 2024 nov. 04 ] Available from: https://dx.doi.org/10.1016/j.yrtph.2024.105669
  • Source: Clinical and Experimental Ophthalmology. Unidade: FCF

    Subjects: NANOPARTÍCULAS, LIPÍDEOS

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      OCCHIUTTO, Marcelo L et al. Intraoperative paclitaxel associated with lipid nanoparticles in trabeculectomy. Clinical and Experimental Ophthalmology, v. 51, n. 6, p. 644-646, 2023Tradução . . Acesso em: 04 nov. 2024.
    • APA

      Occhiutto, M. L., Passos, T. H. M., Freitas, F. R. de, Maranhão, R. C., & Costa, V. P. (2023). Intraoperative paclitaxel associated with lipid nanoparticles in trabeculectomy. Clinical and Experimental Ophthalmology, 51( 6), 644-646.
    • NLM

      Occhiutto ML, Passos THM, Freitas FR de, Maranhão RC, Costa VP. Intraoperative paclitaxel associated with lipid nanoparticles in trabeculectomy. Clinical and Experimental Ophthalmology. 2023 ; 51( 6): 644-646.[citado 2024 nov. 04 ]
    • Vancouver

      Occhiutto ML, Passos THM, Freitas FR de, Maranhão RC, Costa VP. Intraoperative paclitaxel associated with lipid nanoparticles in trabeculectomy. Clinical and Experimental Ophthalmology. 2023 ; 51( 6): 644-646.[citado 2024 nov. 04 ]
  • Source: Journal of Oncology Research and Therapy. Unidade: FCF

    Subjects: ADENOCARCINOMA, NANOPARTÍCULAS

    Versão PublicadaAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      BIGHETTI, Bruna et al. Use of paclitaxel associated to lipid core nanoparticles (LDE) in the second or third line treatment of advanced pancreatic adenocarcinoma. Journal of Oncology Research and Therapy, v. 8, p. 1-7 art. 10192, 2023Tradução . . Disponível em: https://dx.doi.org/10.29011/2574-710X.10192. Acesso em: 04 nov. 2024.
    • APA

      Bighetti, B., Donnarumma, C. D. C., Esper, R. B., Vital, C. G., Morikawa, A. T., Oliveira, J. S. R. de, et al. (2023). Use of paclitaxel associated to lipid core nanoparticles (LDE) in the second or third line treatment of advanced pancreatic adenocarcinoma. Journal of Oncology Research and Therapy, 8, 1-7 art. 10192. doi:10.29011/2574-710X.10192
    • NLM

      Bighetti B, Donnarumma CDC, Esper RB, Vital CG, Morikawa AT, Oliveira JSR de, Maranhão RC, Forones NM. Use of paclitaxel associated to lipid core nanoparticles (LDE) in the second or third line treatment of advanced pancreatic adenocarcinoma [Internet]. Journal of Oncology Research and Therapy. 2023 ; 8 1-7 art. 10192.[citado 2024 nov. 04 ] Available from: https://dx.doi.org/10.29011/2574-710X.10192
    • Vancouver

      Bighetti B, Donnarumma CDC, Esper RB, Vital CG, Morikawa AT, Oliveira JSR de, Maranhão RC, Forones NM. Use of paclitaxel associated to lipid core nanoparticles (LDE) in the second or third line treatment of advanced pancreatic adenocarcinoma [Internet]. Journal of Oncology Research and Therapy. 2023 ; 8 1-7 art. 10192.[citado 2024 nov. 04 ] Available from: https://dx.doi.org/10.29011/2574-710X.10192
  • Source: Journal of Clinical Oncology. Conference titles: American Society Clinical Oncology/ASCO. Unidade: FCF

    Subjects: NANOPARTÍCULAS, QUIMIOTERAPIA, NEOPLASIAS PANCREÁTICAS

    Acesso à fonteHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      BIGHETTI, Bruna e MARANHÃO, Raul Cavalcante e FORONES, Nora Manoukian. LDE-paclitaxel in second or later lines in advanced pancreatic cancer: a phase I trial. Journal of Clinical Oncology. Philadelphia: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.e16298?role=tab. Acesso em: 04 nov. 2024. , 2023
    • APA

      Bighetti, B., Maranhão, R. C., & Forones, N. M. (2023). LDE-paclitaxel in second or later lines in advanced pancreatic cancer: a phase I trial. Journal of Clinical Oncology. Philadelphia: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Recuperado de https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.e16298?role=tab
    • NLM

      Bighetti B, Maranhão RC, Forones NM. LDE-paclitaxel in second or later lines in advanced pancreatic cancer: a phase I trial [Internet]. Journal of Clinical Oncology. 2023 ; 41( 16):[citado 2024 nov. 04 ] Available from: https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.e16298?role=tab
    • Vancouver

      Bighetti B, Maranhão RC, Forones NM. LDE-paclitaxel in second or later lines in advanced pancreatic cancer: a phase I trial [Internet]. Journal of Clinical Oncology. 2023 ; 41( 16):[citado 2024 nov. 04 ] Available from: https://ascopubs.org/doi/pdf/10.1200/JCO.2023.41.16_suppl.e16298?role=tab

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024